PHGE: צמיחת רווחי EPS רבעונית BiomX
BiomX Inc. (PHGE) is betting on the commercialization of phage therapy for the treatment of resistant acne. High-throughput screening is automated here using robotic systems. Quarterly earnings per share growth demonstrates margin dynamics, with the value of 90.30 capturing this metric. Drug production is outsourced to external contractors, which is offset by strategic supply planning and laboratory diversification.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_PHGE_-_BiomX-Inc._-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "BiomX (PHGE): צמיחת רווחי EPS רבעונית מ-04.07.2022 עד 11.09.2026 | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור BiomX Inc. (PHGE)
For BiomX Inc. (PHGE), the cost efficiency of the high-tech cold chain during bacteriophage transportation directly determines the dynamics of net earnings per share. By analyzing the trajectory of quarterly EPS growth, an investor assesses the percentage change in profit relative to the previous period, which allows for the identification of fundamental trend reversal points and the determination of the asset's actual resilience amid changing Fed rates.
